Cudalbu C, Comment A, Kurdzesau F, van Heeswijk RB, Uffmann K, Jannin S, Denisov V, Kirik D, Gruetter R.
Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats.
Phys Chem Chem Phys. 2010 Jun 14;12(22):5818-23.
Ulusoy A, Sahin G, Kirik D.
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13159-64.
Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersén A; The Huntington Study Group PREDICT-HD investigators.
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.
Neurobiol Dis. 2010 Aug 2. [Epub ahead of print]
Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M.
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Eur J Neurosci. 2010 Aug;32(3):409-22.
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A.
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.
Mov Disord. 2010;25 Suppl 1:S174-9.
Björklund T, Carlsson T, Cederfjäll EA, Carta M, Kirik D.
Optimized adeno-associated viral vector-mediated striatal DOPA.
Brain. 2010;133:496-511.
Grealish S, Jönsson ME, Li M, Kirik D, Björklund A, Thompson LH.
The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.
Brain. 2010 Feb;133(Pt 2):482-95.
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M.
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.
PLoS One. 2010 Jan 20;5(1):e8784.
Kornum BR, Stott SR, Mattsson B, Wisman L, Ettrup A, Hermening S, Knudsen GM, Kirik D.
Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain.
Exp Neurol. 2010 Mar;222(1):70-85.
Dodiya HB, Bjorklund T, Stansell Iii J, Mandel RJ, Kirik D, Kordower JH.
Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates.
Mol Ther. 2010 Mar;18(3):579-87.
Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schäfer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D, Lucius R.
Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils.
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):897-909.
Björklund A, Björklund T, Kirik D.
Gene therapy for dopamine replacement in Parkinson's disease.
Sci Transl Med. 2009 Oct 14;1(2):2ps2.
Leriche L, Björklund T, Breysse N, Besret L, Grégoire MC, Carlsson T, Dollé F, Mandel RJ, Déglon N, Hantraye P, Kirik D.
Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy.
J Neurosci. 2009 Feb 4;29(5):1544-53.
Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, Carta M, Kirik D.
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
J Neurochem. 2009 Oct;111(2):355-67.
Ulusoy A, Sahin G, Björklund T, Aebischer P, Kirik D.
Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons.
Mol Ther. 2009 Sep;17(9):1574-84.
Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Brain. 2009;132(Pt 2):319-35.
Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M.
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Exp Neurol. 2009 Sep;219(1):298-307.
Thompson LH, Grealish S, Kirik D, Björklund A.
Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.
Eur J Neurosci. 2009 Aug;30(4):625-38.
Sarkar R, Comment A, Vasos PR, Jannin S, Gruetter R, Bodenhausen G, Hall H, Kirik D, Denisov VP.
Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization.
J Am Chem Soc. 2009 Nov 11;131(44):16014-5.
Björklund T, Kirik D.
Scientific rationale for the development of gene therapy strategies for Parkinson's disease.
Biochim Biophys Acta. 2009 Jul;1792(7):703-13.
Petersén Å, Hult S and Kirik D.
Huntington's disease - new perspectives based on neuroendocrine changes in rodent models.
Neurodegenerative Diseases 2009;6:154-64.
Ramaswamy S, Björklund T, Kordower JH and Kirik D.
Novel gene-based therapeutics targeting the dopaminergic system in Parkinson's disease.
In: Dopamine Handbook (Björklund A, Dunnett S, Iversen L, and Iversen S, eds). Oxford University, 2009:489-497.
Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D.
Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory.
J Neurosci. 2008 Jul 30;28(31):7797-807.
Ulusoy, A, Bjorklund, T, Hermening, S, and Kirik, D.
In vivo gene delivery for development of mammalian models for Parkinson's disease.
Exp Neurol, 2008 Jan:209(1):89-100.
Thompson LH, Kirik D, Björklund A.
Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain.
Exp Neurol. 2008 Sep;213(1):220-8.
Nygren JM, Ljuba K, Breitbach M, Stott S, Thorén L, Roell W, Geisen C, Sasse P, Kirik D, Björklund A, Nerlov C, Felischmann BK, Jovinge S, Jacobsen SE.
Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion.
Nat Cell Biol. 2008 May;10(5):584-92.
Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Brain. 2008;131(Pt 12):3380-94.
Irvin DK, Kirik D, Björklund A, Thompson LH.
In vivo gene delivery to proliferating cells in the striatum generated in response to a 6-hydroxydopamine lesion of the nigro-striatal dopamine pathway.
Neurobiol Dis. 2008 Jun;30(3):343-52.
Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D.
Applications of lentiviral vectors for biology and gene therapy of neurological disorders.
Curr Gene Ther. 2008 Dec;8(6):461-73.
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A.
Involvement of the serotonin system in L-dopa-induced dyskinesias.
Parkinsonism Relat Disord. 2008;14 Suppl 2:S154.
Ulusoy A, Kirik D.
Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?
Exp Neurol. 2008 Aug;212(2):258-60.
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A.
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
Prog Brain Res. 2008;172:465-78.
Kirik D, Gai WP, Jensen PH.
Is alpha-synuclein the culprit of the Parkinsonian neurodegeneration?
Exp Neurol. 2008 Jan;209(1):3-4.
Björklund T, Morizane A, Kirik D and Brundin P.
Future Cell- and Gene-based Therapies for Parkinson’s disease.
In: Therapeutics of Parkinson’s Disease and other Movement Disorders. (Hallett M and Poewe W, eds). Chichester: Wiley, 2008:145-156.
Lane E, Carlsson T, Kirik D, and Dunnett S.
Animal models of Parkinson’s disease.
In: Sourcebook of Model Organisms in Biomedical Research. (Conn, MP, ed.). Totowa: Humana, 2008:313-322.
Breysse, N, Carlsson, T, Winkler, C, Bjorklund, A, and Kirik, D.
The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease.
J Neurosci. 2007 May 30 27(22):5849-56. (2007).
Carlsson, T, Carta, M, Winkler, C, Bjorklund, A, and Kirik, D.
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.
J Neurosci, 2007 Jul 25;27(30):8011-22.
Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D.
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Brain. 2007 Mar;130(Pt 3):799-815.
Carlsson, T, Bjorklund, T, and Kirik, D.
Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy.
Curr Gene Ther, 2007 Apr,7(2):109-20.
Carta M, Carlsson T, Kirik D, Björklund A.
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Brain. 2007 Jul;130(Pt 7):1819-33.
Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Månsson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S.
Murine models of acute neuronopathic Gaucher disease.
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17483-8.
Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M.
Seizure suppression by GDNF gene therapy in animal models of epilepsy.
Mol Ther. 2007 Jun;15(6):1106-13.
Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M.
Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat.
Neuroreport. 2007 Jun 11;18(9):845-50.
Carlsson T, Winkler C, Lundblad M, Cenci MA, Björklund A, Kirik D.
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
Neurobiol Dis. 2006 Mar;21(3):657-68.
Maingay M, Romero-Ramos M, Carta M, Kirik D.
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Neurobiol Dis. 2006 Sep;23(3):522-32.
Stott SR, Kirik D
Targeted in utero delivery of a retroviral vector for gene transfer in the rodent brain.
Eur J Neurosci. 2006 Oct;24(7):1897-906.
Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D.
Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Neuroscience. 2006 Aug 11;141(1):521-31.
Torres EM, Meldrum A, Kirik D, Dunnett SB.
An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections.
J Neurosci Methods. 2006 Nov 15;158(1):64-74.
Kirik D, Georgievska. B, Svendsen C
Delivery of GDNF for Parkinson’s disease: Transition of a neuroprotective treatment strategy from basic sciences to clinical application
In: Restorative therapies in Parkinson's disease. (Olanow CW and Brundin P eds.), London: Kluwer Academic Publishers, 2006:297-316.
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D.
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
J Neurosci. 2005 Jan 26;25(4):769-77.
Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D.
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Brain. 2005 Mar;128(Pt 3):559-69.
Thompson L, Barraud P, Andersson E, Kirik D, Björklund A.
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections.
J Neurosci. 2005 Jul 6;25(27):6467-77. Erratum in: J Neurosci. 2005 Sep 7;25(36).
Sørensen AT, Thompson L, Kirik D, Björklund A, Lindvall O, Kokaia M.
Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts.
Eur J Neurosci. 2005 May;21(10):2793-9.
Barraud P, Thompson L, Kirik D, Björklund A, Parmar M.
Isolation and characterization of neural precursor cells from the Sox1-GFP reporter mouse.
Eur J Neurosci. 2005 Oct;22(7):1555-69.
Popovic N, Maingay M, Kirik D, Brundin P.
Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
Exp Neurol. 2005 May;193(1):65-74.
Kirik D, Breysse N, Björklund T, Besret L, Hantraye P.
Imaging in cell-based therapy for neurodegenerative diseases.
Eur J Nucl Med Mol Imaging. 2005 Dec;32 Suppl 2:S417-34.
Winkler C, Kirik D, Björklund A.
Cell transplantation in Parkinson's disease: how can we make it work?
Trends Neurosci. 2005 Feb;28(2):86-92.
Kirik D, Björklund A.
Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results.
Brain. 2005 Jul;128(Pt 7):1478-9.
Maingay M, Romero-Ramos M, Kirik D.
Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease.
CNS Spectr. 2005 Mar;10(3):235-44.
Romero-Ramos M, Maingay M, Kirik D.
Parkinson’s disease: New and old models.
In: Neuroprotection: Models, mechanisms, and therapies. (Bähr M ed.), Weinheim: Wiley-VCH Verlag, 2005:31-50.
Georgievska B, Carlsson T, Lacar B, Winkler C, Kirik D.
Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
Eur J Neurosci. 2004 Dec;20(11):3121-30.
Georgievska B, Kirik D, Björklund A.
Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system.
J Neurosci. 2004 Jul 21;24(29):6437-45.
Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C.
Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector.
Hum Gene Ther. 2004 Oct;15(10):934-44.
Kirik D, Georgievska B, Björklund A.
Localized striatal delivery of GDNF as a treatment for Parkinson disease.
Nat Neurosci. 2004 Feb;7(2):105-10.
Winkler C, Kirik D.
Replacement of dopamine and restoration of striatal function.
In: Brain damage and repair: From molecular research to clinical therapy. (Herdegen T, Delgrado-Garcia JM, eds.), London: Kluwer Academic Publishers, 2004:549-562.
Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A.
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2884-9.
Rosenblad C, Georgievska B, Kirik D.
Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system.
Eur J Neurosci. 2003 Jan;17(2):260-70.
Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE.
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).
Exp Neurol. 2003 Nov;184(1):536-48.
Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O.
Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats.
Neurobiol Dis. 2003 Dec;14(3):542-56.
Gustafsson E, Andsberg G, Darsalia V, Mohapel P, Mandel RJ, Kirik D, Lindvall O, Kokaia Z.
Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke.
Eur J Neurosci. 2003 Jun;17(12):2667-78.
Kirik D, Björklund A.
Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors.
Trends Neurosci. 2003 Jul;26(7):386-92.
Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
J Neurosci. 2002 Apr 1;22(7):2780-91.
Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A.
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4708-13.
Georgievska B, Kirik D, Björklund A.
Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
Exp Neurol. 2002 Oct;177(2):461-74.
Winkler C, Kirik D, Björklund A, Cenci MA.
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Neurobiol Dis. 2002 Jul;10(2):165-86.
Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O.
Neuronal replacement from endogenous precursors in the adult brain after stroke.
Nat Med. 2002 Sep;8(9):963-70.
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA.
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Eur J Neurosci. 2002 Jan;15(1):120-32.
Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A.
Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Neuroreport. 2002 Jan 21;13(1):75-82.
Kirik D, Georgievska B, Rosenblad C, Björklund A.
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Eur J Neurosci. 2001 Apr;13(8):1589-99.
Kirik D, Winkler C, Björklund A.
Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.
J Neurosci. 2001 Apr 15;21(8):2889-96.
Kirik D, Rosenblad C, Bjorklund A, Mandel RJ.
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
J Neurosci. 2000 Jun 15;20(12):4686-700.
Kirik D, Rosenblad C, Björklund A.
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
Eur J Neurosci. 2000 Nov;12(11):3871-82.
Rosenblad C, Kirik D, Björklund A.
Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Exp Neurol. 2000 Feb;161(2):503-16.
Rosenblad C, Grønborg M, Hansen C, Blom N, Meyer M, Johansen J, Dagø L, Kirik D, Patel UA, Lundberg C, Trono D, Björklund A, Johansen TE.
In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.
Mol Cell Neurosci. 2000 Feb;15(2):199-214. Erratum in: Mol Cell Neurosci 2001 Sep;18(3):332-3.
Fricker-Gates RA, Winkler C, Kirik D, Rosenblad C, Carpenter MK, Björklund A.
EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum.
Exp Neurol. 2000 Oct;165(2):237-47.
Winkler C, Kirik D, Björklund A, Dunnett SB.
Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement.
Prog Brain Res. 2000;127:233-65.
Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ.
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Brain Res. 2000 Dec 15;886(1-2):82-98.
Rosenblad C, Kirik D, Björklund A.
Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants.
Neuroreport. 1999 Jun 3;10(8):1783-7.
Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A.
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Eur J Neurosci. 1999 May;11(5):1554-66.
Kirik D, Rosenblad C, Björklund A.
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Exp Neurol. 1998 Aug;152(2):259-77.
Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E Jr, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, Phillips HS.
Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
J Neurosci. 1998 Jul 1;18(13):4929-37.
Björklund A, Rosenblad C, Winkler C, Kirik D.
Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.
Neurobiol Dis. 1997;4(3-4):186-200.
Page Manager: Jenny Månsson
Last modified: 2010-09-28
